Inter-individual variability in response to clopidogrel in patients with coronary artery disease;Indywidualna zmienność odpowiedzi na leczenie klopidogrelem w chorobie niedokrwiennej serca

Kardiologia Polska

Volumn 62, Issue 2, 2005, Pages 108-118

  Dziewierz, Artur ^a   Dudek, Dariusz ^a   Heba, Grzegorz ^a   Rakowski, Tomasz ^a   Mielecki, Waldemar ^a   Dubiel, Jacek S ^a   Wysocki, Henryk ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b AM   (Poland)

Author keywords

Antiplatelet treatment; Clopidogrel; Resistance to treatment; Stable angina

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; STATINE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

EID: 18044370882     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348, 1329-1339.
2. Yusuf S., Zhao F., Mehta S.R. et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345, 494-502.
3. Mehta S.R., Yusuf S., Peters R.J. et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358, 527-533.
4. Steinhubl S.R., Berger P.B., Mann J.T. III et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002, 288, 2411-2420.
5. Gurbel P.A., Bilden K.P., Hiatt B.L. et al.: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107, 2908-2913.
6. Lau W.C., Waskell L.A., Watkins P.B. et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003, 107, 32-37.
7. Gurbel P.A., Cummings C.C., Bell C.R. et al.: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am. Heart J. 2003, 145, 239-247.
8. Muller I., Besta F., Schulz C. et al.: Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 2003, 89, 783-787.
9. Lau W.C., Gurbel P.A., Watkins P.B. et al.: Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. Circulation 2004, 109, 166-171.
10. Neubauer H., Gunesdogan B., Hanefeld C. et al.: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur. Heart J. 2003, 24, 1744-9.
11. Mitsios J.V., Papathanasiou A.I., Rodis F.I. et al.: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004, 109, 1335-1338.
12. Saw J., Steinhitbl S.R., Berger P.B. et al.: Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003, 108, 921-924.
13. Wienbergen H., Gitt A.K., Schiele R. et al.: Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am. J. Cardiol. 2003, 92, 285-288.
14. Seyfarth H.J., Koksch M., Roethig G. et al.: Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am. Heart. J. 2002, 143, 118-23.
15. Kastrati A., Mehilli J., Schhlen H. et al.: A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. N. Engl. J. Med. 2004, 350, 232-238.
16. Fontana P., Dupont A., Gandrille S. et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003, 108, 989-995.
17. O'Donnell C.J., Larson M.G., Feng D. et al.: Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation 2001, 103, 3051-3056.
18. Soffer D., Moussa I., Harjai K.J. et al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter. Cardiovasc. Interv. 2003, 59, 21-25.
19. Steinhubl S.R., Talley J.D., Braden G.A. et al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU - Assessing Ultegra) multicenter study. Circulation 2001, 103, 2572-2578.
20. Kabbani S.S., Watkins M.W., Ashikaga T. et al.: Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am. J. Cardiol. 2003, 91, 876-878.
21. Gurbel P.A., Buden K.P.: Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 2003, 91, 1123-1125.
22. Carville D.G., Schleckser P.A., Guyer K.E. et al.: Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J. Extra. Corpor. Technol. 1998, 30, 171-177.
23. Gum P.A., Kottke-Marchant K., Welsh P.A. et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 2003, 41, 961-965.
24. Eikelboom J.W., Hankey G.J.: Aspirin resistance: a new independent predictor of vascular events? J. Am. Coll. Cardiol. 2003, 41, 966-968.